GREAT NECK, N.Y. & PLANTATION, Fla.--(BUSINESS WIRE)--Neogenix Oncology, Inc. (Neogenix) and Goodwin Biotechnology, Inc. (GBI) announced today that they have entered into an agreement for process development and manufacturing of Neogenix’s first therapeutic product, NPC-1C, a novel monoclonal antibody intended for the treatment of advanced pancreatic cancer. On successful completion of this phase of development, and with FDA approval, Neogenix will begin Phase I and Phase II trials of the product, which are currently planned for the first half of 2008.
